Indications: entyvio (vedolizumab) is indicated for adult patients with moderately to severely active ulcerative colitis (uc) or crohns disease (cd) who have had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids, or who have had an inadequate response with, lost response to, or were intolerant to an immunomodulator or a tumor necrosis factor (tnf) blocker.recommended dosage in uc and cd: 300 mg infusedintravenously over approximately 30 minutes at zero, two and sixweeks, then every eight weeks thereafter.reconstitute entyvio lyophilized powder with sterile water forinjection and dilute in 250 ml of sterile 0.9% sodium chlorideinjection or sterile lactated ringers injection